2141-V11

DRUG2 trials

Sponsors

Darell Bigner

Conditions

Glioma, MalignantNewly Diagnosed MGMT Unmethylated Glioblastoma

Phase 1

Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

RecruitingNCT04547777

Darell BignerGlioma, Malignant

Start: 2021-07-09End: 2028-06-01Target: 90Updated: 2026-06-04

D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

RecruitingNCT05734560

Darell BignerNewly Diagnosed MGMT Unmethylated Glioblastoma

Start: 2023-09-06End: 2028-10-31Target: 50Updated: 2025-10-06

Related Papers

TIP-27. An assessment of the Tumor Monorail Device (TMD) for repeated sampling as part of a trial evaluating the combination of D2C7-IT and an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery (CED) and cervical perilymphatic injections (CPLIs) of 2141-V11 in recurrent glioblastoma (rGBM) patients

Neuro-Oncology2025-11-01

CTIM-30. INVESTIGATION OF THE COMBINATION OF D2C7-IT WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) WHEN ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 COMPARED TO D2C7-IT CED MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM)

Neuro-Oncology2025-11-01

CTIM-13. D2C7-IT IN COMBINATION WITH AN FC-ENGINEERED ANTI-HUMANCD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS (CPLIS) OF 2141-V11 IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM)

Neuro-Oncology2024-11-011 citations

Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models

Science Translational Medicine2023-02-0825 citations

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).

Journal of Clinical Oncology2022-06-0110 citations